2019 News Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012

Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population

04/23/19

Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants

04/18/19

Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)

04/15/19

Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue

04/12/19

Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor

04/11/19

Mallinckrodt's INOmax™ (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery

04/10/19

Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics

04/09/19

Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS)

04/05/19

Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality

03/28/19

Mallinckrodt plc To Report Earnings Results For First Quarter 2019

03/27/19

Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation

03/26/19

Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO)

03/18/19

Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners

03/15/19

Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

03/04/19

Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities

02/26/19

Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG

02/25/19

Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

02/20/19

Mallinckrodt To Present At Barclays Global Healthcare Conference

02/12/19

Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA)

02/05/19

Mallinckrodt plc To Report Earnings Results For Fourth Quarter And Fiscal 2018

01/14/19

Mallinckrodt Will Respond to U.S. House Committee on Oversight and Reform Request for Information on H.P. Acthar® Gel

01/14/19

Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation

01/03/19
Print Page Print Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts